Molecular Type 2 Diabetes Biomarker Identified
|
By LabMedica International staff writers Posted on 23 Feb 2016 |
|
Image: The HiScan SQ scanner (Photo courtesy of Illumina).
Type 2 diabetes mellitus (DM) is an established risk factor for a wide range of vascular diseases, including ischemic stroke (IS) as well as heart attacks, neuropathy and blindness.
Type 2 diabetes is a chronic illness characterized by the presence of elevated blood glucose levels and it accounts for between 80% and 90% of diabetes cases and is one of the major cardiovascular risk factors.
Scientists at the Hospital del Mar Medical Research Institute (Barcelona, Spain) investigated DNA methylation in the blood samples of a cohort of 355 stroke patients using a state-of-the-art technique that allows them to study more than 450,000 methylation points in the genome. In addition, the study compared the methylation profiles of diabetics and non-diabetics as well as their levels of glycosylated hemoglobin (HbA1c), a biomarker that indicates blood glucose levels over the past three months.
DNA samples were extracted from whole peripheral blood collected in 10 mL EDTA tubes. The Chemagic Magnetic Separation Module I system (Chemagen, Baesweiler, Germany) was used for DNA isolation in one cohort, and the Autopure LS (Qiagen, Hilden, Germany) in another. Genome-wide DNA methylation was assessed using the Illumina HumanMethylation450 Beadchip (Illumina Netherlands; Eindhoven, Netherlands) and the arrays were scanned with the Illumina HiScan SQ scanner.
The study was subsequently replicated in two cohorts from independent populations, with 167 and 645 patients respectively, confirming the relationship between Thioredoxin Interacting Protein (TXNIP) methylation, diabetes and glucose level dysfunction. Methylation of TXNIP was inversely and intensely associated with HbA1c levels specifically related to diabetic patients with poor control of glucose levels. The authors concluded that hypomethylation of the TXNIP gene is related to type 2 DM. The inverse relationship between TXNIP methylation and HbA1c values suggests that TXNIP hypomethylation is a consequence of sustained hyperglycemia levels.
Carolina Soriano-Tárraga, PhD, the lead author of the study said, “The methylation of this gene could be used as an early biomarker of dysfunction in the control of glucose levels. We are currently studying the implications and specific role of this gene in diabetes. In the future it could provide a possible therapeutic target for treating diabetes or controlling glucose concentrations.” The study was published originally online on December 7, 2015, in the journal Human Molecular Genetics.
Related Links:
Hospital del Mar Medical Research Institute
Chemagen
Illumina Netherlands
Type 2 diabetes is a chronic illness characterized by the presence of elevated blood glucose levels and it accounts for between 80% and 90% of diabetes cases and is one of the major cardiovascular risk factors.
Scientists at the Hospital del Mar Medical Research Institute (Barcelona, Spain) investigated DNA methylation in the blood samples of a cohort of 355 stroke patients using a state-of-the-art technique that allows them to study more than 450,000 methylation points in the genome. In addition, the study compared the methylation profiles of diabetics and non-diabetics as well as their levels of glycosylated hemoglobin (HbA1c), a biomarker that indicates blood glucose levels over the past three months.
DNA samples were extracted from whole peripheral blood collected in 10 mL EDTA tubes. The Chemagic Magnetic Separation Module I system (Chemagen, Baesweiler, Germany) was used for DNA isolation in one cohort, and the Autopure LS (Qiagen, Hilden, Germany) in another. Genome-wide DNA methylation was assessed using the Illumina HumanMethylation450 Beadchip (Illumina Netherlands; Eindhoven, Netherlands) and the arrays were scanned with the Illumina HiScan SQ scanner.
The study was subsequently replicated in two cohorts from independent populations, with 167 and 645 patients respectively, confirming the relationship between Thioredoxin Interacting Protein (TXNIP) methylation, diabetes and glucose level dysfunction. Methylation of TXNIP was inversely and intensely associated with HbA1c levels specifically related to diabetic patients with poor control of glucose levels. The authors concluded that hypomethylation of the TXNIP gene is related to type 2 DM. The inverse relationship between TXNIP methylation and HbA1c values suggests that TXNIP hypomethylation is a consequence of sustained hyperglycemia levels.
Carolina Soriano-Tárraga, PhD, the lead author of the study said, “The methylation of this gene could be used as an early biomarker of dysfunction in the control of glucose levels. We are currently studying the implications and specific role of this gene in diabetes. In the future it could provide a possible therapeutic target for treating diabetes or controlling glucose concentrations.” The study was published originally online on December 7, 2015, in the journal Human Molecular Genetics.
Related Links:
Hospital del Mar Medical Research Institute
Chemagen
Illumina Netherlands
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Immunofluorescence Analyzer
IFA System
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Latest Clinical Chem. News
- New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
- Multi-Protein Blood Test Improves Staging of Alzheimer’s Disease
- Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury
- Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
- AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer
- Compact Prenatal Screening System Expands Access to Preeclampsia Testing
- Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
- Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
- Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
Channels
Clinical Chemistry
view channel
Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury
Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more
Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read more
Microbiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read more
Pathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Technology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more